Dr. Clifford A. Hudis on the Importance of In-Breast Response Rates in Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer and in-breast response rates.

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, discusses carboplatin in triple-negative breast cancer. Huddis says that while carboplatin does not definitively produce long-term outcomes, the drug does improve in-breast response rate, which could be important in some cases. He adds that those cases would include inoperable breast cancer that medical professionals would be looking to convert into an operable case.